Pharmacologic Substance – Page 125

GSK’s Vaccine Sales Surge Continues, Boosting 2024 Outlook

12 months ago talkbio0Tagged 2024, COVID19 (disease), Drug Industry, Health Care Sector, Projections and Predictions, revenue growth, Shingrix, SmithKline Beecham, SmithKline Beecham, Vaccines

GSK, GlaxoSmithKline, vaccine sales, 2024 forecasts, pharmaceutical industry, revenue growth, COVID-19 vaccines, Shingrix, healthcare sector

Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

12 months ago talkbio0Tagged Angioedemas, Hereditary, Collaboration, Editas Medicine, KalVista, Myers, Partnership, preclinical program, squibb, T cell therapy

Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.

Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database

12 months ago talkbio0Tagged Drug Development, Drug Industry, heroin, Intellectual Property, Legal patent, Nordisk, Ozempic, United States Federal Trade Commission, United States Food and Drug Administration

FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.

Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity

12 months ago talkbio0Tagged Capacity, Drug Industry, drug manufacturing, Eli Lilly, financial outlook, Mounjaro, production, Zepbound

Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.

Novartis Invests $180M in PeptiDream to Boost Radiopharmaceutical Development

12 months ago talkbio0Tagged Cancer Therapeutic Procedure, cellular targeting, Drug Development, Investments, Isotopes, Novartis, Partnership, PeptiDream, Radioactivity, Radiopharmaceuticals

Novartis, PeptiDream, radiopharmaceuticals, investment, drug development, partnership, targeted therapies, cancer treatment, radioactive isotopes.

FDA Approval Milestones: X4 Pharmaceuticals, Pfizer, and Genmab Secure Nods for Rare Disease and Cervical Cancer Treatments

12 months ago talkbio0Tagged Biotechnology, Drug Approval, Genmab, Health care facility, Malignant tumor of cervix, Pfizer, United States Food and Drug Administration

FDA, X4 Pharmaceuticals, Pfizer, Genmab, rare disease, cervical cancer, drug approval, treatment, healthcare, biotechnology.

X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder

12 months ago talkbio0Tagged Antagonist muscle action, Approved, CXCR4 gene, United States Food and Drug Administration, WHIM syndrome, Xolremdi

X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

12 months ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.